Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Human NAT1: overview
- NAT1 specific ligands
- Screening for NAT substrates & inhibitors
- Biomarker detection in breast cancer (1)
- Biomarker detection in breast cancer (2)
- A single binding site
- Naphthoquinone inhibits acetylation activity
- Naphthoquinone 1 inhibits AcCoA hydrolysis
- R127 mutation blocks inhibition by naphthoquinone
- R127 in hNAT1 and mNAT2
- Improving NAT1 detection
- NAT1 knock-down alters cell growth & survival
- Status of NAT1 research
- Arylamine N-acetyltransferases (recap)
- Nat in fungi metabolise anti-fungal toxin
- Activity of fungal Nat enzymes
- Nat in prokaryotes including mycobacteria
- Prokaryotic Nats
- Active site of Mycobacterium smegmatis Nat
- Active site of Pseudomonas aerogunosa Nt
- Life cycle of M. tuberculosis
- Return to N-acetylation of isoniazid (INH)
- KatG and Nat
- Nats in prokaryotes
- Nats affect lipid levels in cells
- M. bovis BCG phenotype in nat KO cells (1)
- M. bovis BCG phenotype in nat KO cells (2)
- M. bovis BCG phenotype in nat KO cells (3)
- M. bovis BCG phenotype in nat KO cells (4)
- Inhibiting Nat and mycolic acid
- Summary: alteration of nat expression
- Mycobacterial Nat specific ligands
- Detecting Nat substrates & inhibitors
- Mycobacterial Nat inhibitors identified from screen
- Nat as an anti-tubercular target
- Triazole vs. mycobacteria
- Growth inside macrophage is affected
- Synthetic analogues of 190
- Docking the compound into the active site of Nat
- Piperidinol inhibition of mycobacterial Nat
- Inhibition by piperidinol
- Piperidinol in the presence of mycobacterial Nat
- Binding of piperidinol fragment
- Structure of TB Nat now available
- TB Nat inhibitors
- Summary: chemical inhibition
- The future
- Acknowledgments
Topics Covered
- Mechanism of action
- Reaction substrates
- Isoform substrate profiles
- Isoenzymes NAT1 and NAT2
- Regulation of gene expression
- Pharmacogenetics
- Phenotype/genotype correlation
- Ethnic variation
- Transgenic mouse models
- NAT protein structures
- NAT as a biomarker in breast cancer
- NAT inhibitors as diagnostic agents
- NAT in mycobacteria
- NAT inhibitors as an approach to potential anti-tubercular agents
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sim, E. (2016, July 28). Arylamine N-acetyltransferases 3 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/IDJJ9816.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Edith Sim has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Arylamine N-acetyltransferases 3
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Arylamine
N-acetyltransferases. Part 3
I'm Edith Sim,
and I have been working
on these enzymes
for over 20 years.
0:10
So human NAT1, to recap,
is widespread in
tissue distribution,
shows genetic polymorphism,
N-acetylates p-aminobenzoic acid,
and N-acetylates p-abaglu
a folate catabolite.
It hydrolyses acetylCoA
in the presence of folate.
It's clearly expressed in
early development.
It's over-expressed
in ER positive breast cancer.
And it's linked to folate
and acetylCoA homeostasis.
0:40
In order
to explore this further,
it was felt important
to identify
NAT1 specific inhibitors.
0:51
This was done, again,
you've seen this slide before,
but just to emphasize,
this was done to allow a library
of over 5,000 compounds
to be screened
with recombinant
specific enzymes
including human NAT1.
1:11
What came out of this
was a specific NAT1 inhibitor,
identified as naphthoquinone,
which when it binds
to human NAT1
changes color from red to blue.
This is important
because if NAT1 is a biomarker
for breast cancer,
then having something
which would
specifically detect it
is particularly important.